Posted by Michael Wonder on 04 Feb 2026
AbbVie submits regulatory applications to FDA and EMA for upadacitinib (Rinvoq) in adults and adolescents with vitiligo
3 February 2026 - Submissions are supported by data from the Phase 3 Viti-Up clinical studies demonstrating upadacitinib achieved the co-primary endpoints of at least a 50% improvement.
AbbVie today announced that it has submitted applications for a new indication to the US FDA and EMA for upadacitinib (Rinvoq; 15 mg, once daily) for the treatment of adult and adolescent patients living with non-segmental vitiligo.
